Resumen
Patients with hematological malignancies have a higher risk of hospital admission, critical care and death when they suffer from COVID-19. In this group of patients, vaccination and boosters have been proposed to mitigate the risk of complications. However, it is possible to observe a diminished rate of humoral and cellular response. In this review, evidence is shown about the response to COVID-19 vaccination, considering some specific pathologies and treatments that can affect such response in a significant account. Patients with malig-nant neoplasm must be considered at risk of COVID-19 complications, even after a complete vaccine schedule and boosters. Surveillance must be maintained after vaccination over these patients and other strategies must be considered (drugs, monoclonal antibodies) for prevention and management of COVID-19.
Título traducido de la contribución | Immunological response to vaccination and risk of COVID-19 in adults with hematological malignancies |
---|---|
Idioma original | Español |
Páginas (desde-hasta) | 228-235 |
Número de páginas | 8 |
Publicación | Revista Chilena de Infectologia |
Volumen | 40 |
N.º | 3 |
DOI | |
Estado | Publicada - jun. 2023 |
Publicado de forma externa | Sí |
Palabras clave
- COVID-19
- hematologic neoplasms
- immunosuppression therapy
- vaccination